Dr Richard Barker, Director General of the ABPI, said: “Collectively, the measures announced today by Lord Darzi represent the basis for a huge leap forward in driving the use of best available treatment, including the uptake of NICE guidance, across the NHS.
“The task is now to deliver on the promise, so that people across the UK have full and fair access to innovative, life-extending medicines, demonstrated to be clinically-effective and cost-effective.
“These measures are good news for patients, who can now look forward to receiving the same standard of care wherever they live, rather than on the basis of a postcode lottery.
“Britain’s innovative pharmaceutical industry will also gain, by serving a more innovative customer, one that will also be a more attractive location for future clinical trials - a further benefit for UK patients.”
Chris Brinsmead, president of the ABPI, said: “We welcome a series of measures that offer the opportunity to effect a seismic change in patients' right to access the best and most modern medicines based on clinical need. We look forward to working in partnership with Government and other stakeholders to ensure that this opportunity is realised.”
About the ABPI:
The Association of the British Pharmaceutical Industry (ABPI) has 150 members including the large majority of the research-based pharmaceutical companies operating in the UK, both large and small. Our member companies research, develop, manufacture and supply more than 80 per cent of the medicines prescribed through the National Health Service (NHS). For further information visit: www.abpi.org.uk
Media contact: ABPI Press office, 020 7747 1410.